Well researched thoughtful post- thank you. I would like to be more optimistic about the anti-amyloid drugs but until real clinical improvement is demonstrated convincingly( especially with the significant risks and cost), I will remain very skeptical. And wouldn’t Pharma just love to move into the primary prevention market here with virtually unlimited customer base?
As a health care aide and Homecare worker, I have seen this in use by one of my clients. The improvement was quite good, but the family simply could not afford the treatment. After that the clients decline was rapid. Tragic to see the client return to ‘normal’ and then not. I might advise not bothering at all unless you can afford the long term costs. The heartbreak is not worth it.
Hi Hussein, thank you for this article. I was wondering if you have any similar analysis on obicetrabib based on recently reported biomarker data based on the prespecified part of the Broadway phase 3 trial? I realise there is no readout as yet re clinical changes. Your thoughts would be appreciated. Menarini had made and ema accepted some level of pre marketing application. A near 20% difference between placebo and active drug has been reported in E4/4 group. How exciting or not is this at this stage of information?
Its premature to market indications based on a retrospective analysis of a past trial. These are exciting but yet preliminary and would support a direct trial.
Well researched thoughtful post- thank you. I would like to be more optimistic about the anti-amyloid drugs but until real clinical improvement is demonstrated convincingly( especially with the significant risks and cost), I will remain very skeptical. And wouldn’t Pharma just love to move into the primary prevention market here with virtually unlimited customer base?
As a health care aide and Homecare worker, I have seen this in use by one of my clients. The improvement was quite good, but the family simply could not afford the treatment. After that the clients decline was rapid. Tragic to see the client return to ‘normal’ and then not. I might advise not bothering at all unless you can afford the long term costs. The heartbreak is not worth it.
The ability of these drugs to penetrate the blood / brain barrier is in itself a big plus, no? Am I correct that hadnt been possible before?
Hi Hussein, thank you for this article. I was wondering if you have any similar analysis on obicetrabib based on recently reported biomarker data based on the prespecified part of the Broadway phase 3 trial? I realise there is no readout as yet re clinical changes. Your thoughts would be appreciated. Menarini had made and ema accepted some level of pre marketing application. A near 20% difference between placebo and active drug has been reported in E4/4 group. How exciting or not is this at this stage of information?
Its premature to market indications based on a retrospective analysis of a past trial. These are exciting but yet preliminary and would support a direct trial.
Thanks, we will see how it plays out. I believe a specific , rather than prespecified sub group trial is planned for q3 this year.